Omega-3 index

ND-recommended test reviewed: Omega-3 index.
Indications reviewed: cardiovascular risk assessment, guiding omega-3 supplementation.
Not ordered. Rationale discussed: Omega-3 Index is a population-level epidemiological biomarker; no guideline identified recommending individual-patient testing to guide care. Ref: Harris et al 2017, Omega-3 Index and coronary heart disease mortality.
Patient informed test available privately via ND. Patient given info page: https://labs.ajaxharwoodclinic.com/omega-3-index/patient
Revisit if: a specific concern emerges for which a validated test exists.

Indicated when

None recorded.

Not indicated when

• —Individual patient cardiovascular risk assessment or as a treatment target: the Omega-3 Index (red blood cell EPA+DHA as a percent of total fatty acids) has been studied as a population-level, epidemiological risk biomarker across cohort studies, with proposed but not universally adopted clinical cut-points, rather than as a validated individual-patient decision-making test [1]
• —Guiding omega-3 supplementation dosing in primary care
• —Investigating fatigue, joint pain, or general wellness

Why not

The Omega-3 Index is a real, published biomarker, calculated as EPA+DHA content expressed as a percent of total red-blood-cell fatty acids, and a meta-analysis of 10 cohort studies found an inverse association between a higher index and coronary heart disease mortality, supporting proposed therapeutic target cut-points of <4% (higher risk) and >8% (lower risk) [1]. That evidence is epidemiological and population-level, though: it does not establish that measuring an individual patient's index and acting on the result (e.g., adjusting supplementation) improves outcomes for that patient, and no Canadian or international clinical guideline recommending routine Omega-3 Index testing in primary care was located in this session (an evidence gap, not a stated 'don't test' recommendation; see evidence_notes). It is also not the same test as 'free fatty acids' (CONO item 62 / OHIP L099), a distinct, unrelated assay (see cono_orderable.note).

Better first step

For patients interested in omega-3 intake for cardiovascular health, discuss diet (fatty fish intake) or a standard-dose supplement directly; a baseline or follow-up Omega-3 Index is not needed to have this conversation, since there is no validated individual-patient action threshold established for primary care use.

Typical ND rationale

An ND may order an Omega-3 Index reasoning that it directly measures omega-3 fatty acid status in red blood cells, giving an objective way to confirm a deficiency and to track whether supplementation is working, rather than relying on dietary history alone.

Ontario coverage & CONO orderability

OHIP status

uninsured

The Omega-3 Index by that name does not appear in the 2026 Schedule of Benefits for Laboratory Services. 'Fatty acids, free' (L099) is listed in the Schedule, but that is a distinct assay (non-esterified/free fatty acids, used in different clinical contexts such as suspected fatty acid oxidation disorders or fasting studies), not the Omega-3 Index; see cono_orderable.note. This is recorded as unverified because the Omega-3 Index specifically, as a branded/specialty send-out test (e.g., OmegaQuant-type testing), was not found addressed by any Ontario coverage source in this session. Coverage update (reconciliation pass): LifeLabs' Non-OHIP Billable Test List (2025, republished by an Ontario hospital lab) lists this test as patient-paid in community labs. This is secondary evidence, not a ministry statement.

CONO orderable

No

CONO item 62, blood, is 'Fatty acids, free' (matching OHIP L099 'Fatty acids, free'); this measures non-esterified (free) fatty acids in serum, a distinct assay from the Omega-3 Index, which requires a red-blood-cell membrane fatty acid composition analysis (EPA+DHA as a percent of total fatty acids). The two do NOT match. No CONO line item corresponding to the Omega-3 Index by name was found in this session, so it is recorded as not CONO-orderable under any current code; it would be a specialty send-out test if offered.

Linked conditions

• tired ↗

Counselling script

“The Omega-3 Index is a real measurement, and higher levels have been linked to lower heart disease death rates across large groups of people. But no guideline recommends testing it to guide one person's care. If omega-3s interest you, we can talk about diet and whether a supplement makes sense for you, without this test.”

Revisit if

• —A specific, testable clinical concern emerges (this test does not have a defined revisit trigger of its own)

References

1. [1]Harris, Del Gobbo, Tintle (2017). The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. linkThe Omega-3 Index is a validated biomarker of omega-3 fatty acid tissue levels, used in several cohort studies; a 10-cohort analysis found an inverse association with coronary heart disease mortality and supported cut-points of <4% and >8%
2. [2]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkCommunity lab tests are insured only when ordered under the Schedule by an authorized prescriber
3. [3]Government of Ontario (e-Laws) (2026). Health Insurance Act, R.R.O. 1990, Reg. 552: General, s. 22 (insured laboratory services). linkA lab test is insured only when ordered by a physician, midwife, or NP who has clinically assessed the patient
4. [4]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services
5. [5]LifeLabs (republished by Norfolk General Hospital laboratory) (2025). LifeLabs Non-OHIP Billable Test List (republished by Norfolk General Hospital laboratory, effective 2025). linkListed as a non-OHIP (patient-paid) test at LifeLabs Ontario, 2025